Elicio Therapeutics, Inc. - 8-K Filing
Elicio Therapeutics reported Q1 2026 financial results with a net loss of $11.8 million (or $0.65 per share) compared to $11.2 million in the same period last year, driven by R&D expenses of $6.8 million and G&A expenses of $3.8 million. The company raised approximately $13.0 million through its at-the-market program as cash reserves stood at $14.9 million as of March 31, 2026, expected to last into Q4 2026. It also provided updates on the AMPLIFY-7P Phase 2 trial for ELI-002 7P in pancreatic cancer, with a primary DFS analysis anticipated mid-year. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ELTX